Sunday, October 19, 2025
Twitter Vimeo VKontakte Youtube
Home Authors Posts by Namitha Thambi

Namitha Thambi

Namitha Thambi
63 POSTS 0 COMMENTS
Cipla’s Icatibant Gets USFDA Approval
News

Cipla’s Icatibant Gets USFDA Approval To Treat A Rare Genetic Disorder

Namitha Thambi - 0
Cipla Prices Remdesivir At 4000
News

Cipla’s Remdesivir Becomes The Cheapest COVID-19 Drug At A Price Of...

Namitha Thambi - 0
SII To Launch COVID-19 Vaccine
News

Serum Institute Of India Hopes To Launch COVID-19 Vaccine By The...

Namitha Thambi - 0
CRISPR based COVID-19 test
News

Sherlock Biosciences to Develop First Ever Point of Care Test for...

Namitha Thambi - 0
Inovio's Coronavirus Vaccine
News

Inovio’s Coronavirus Vaccine Shows Promising Results In Early Stage Trial

Namitha Thambi - 0
Hydroxychloroquine Clinical Trials Resume
News

COVID-19: Clinical Trials Of Hydroxychloroquine Resumes

Namitha Thambi - 0
Glenmark's Cholesterol lowering drugs
News

Glenmark Pharma’s Cholesterol Lowering Drugs Get USFDA Approval

Namitha Thambi - 0
Remdesivir price in India
News

Cipla To Price Remdesivir For COVID-19 Under Rs 5,000

Namitha Thambi - 0
Both the World Health Organization (WHO) and NIH’s National Heart, Lung, and Blood Institute (NHLBI) have halted hydroxychloroquine's clinical studies conducted to assess the safety and effectiveness of the drug to treat adults with Covid-19 and Novartis, due to its inability to recruit enough patients, ended the Phase III trials of the same drug. One week before, the FDA had revoked its emergency use authorization (EUA) for hydroxychloroquine due to a randomized controlled clinical trial that showed no clinical benefit and the lack of consistent replication of earlier promising results. A data and safety monitoring board (DSMB) found that hydroxychloroquine is not beneficial in treating COVID-19, compared to placebo. However, NIH noted that the drug is not harmful. DSMB recommended the National Heart, Lung, and Blood Institute (NHLBI) to halt the study after a fourth interim analysis.  The randomized, blinded, placebo-controlled clinical trial was conducted in more than 500 patients infected with the novel coronavirus, among which 470 were recruited at the time of trial’s closure. 400mg hydroxychloroquine was given twice a day to the participants for two doses, followed by 200mg twice daily for the next eight doses, or a placebo twice daily for five days. Meanwhile, Novartis, a Swiss pharmaceutical company suspended the phase III clinical trials of hydroxychloroquine, as the completion of the trial was infeasible due to enrollment challenges. No conclusions have been made on the efficacy of the drug in treating COVID-19 and no safety issues have been reported, the company noted. Due to the recruitment challenges, the clinical team was unable to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with Covid-19, said Novartis. However, Novartis will continue to supply HCQ upon government requests and for certain ongoing investigator-initiated trials (IITs). Since HCQ showed no benefit compared to standard of care in reducing deaths, the World Health Organization also halted the clinical trials of hydroxychloroquine on June 17. Source
News

NIH, WHO And Novartis Ended Hydroxychloroquine Trials For COVID-19

Namitha Thambi - 0
India Import 80% APIs From China 
News

India China Conflicts To Affect 80% Pharma Raw Material Supply

Namitha Thambi - 0
1234...7Page 3 of 7
- Advertisement -

MOST POPULAR

HOT NEWS

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© Rasayanika Biotechnologies India Pvt Ltd